This indicated that BCL-2 and c-MYC may synergize to transform B lymphoid cells, but he held a lingering worry that if the Eμ-Myc transgenic mice that provided the bone marrow had a pre-clinical lymphoma, the results might have been skewed. This evidence concerns the gene BCL2 and lymphoma.